Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Kazia Therapeutics ( (KZIA) ) has issued an announcement.
On June 11, 2025, Kazia Therapeutics announced significant preclinical findings published in Molecular Cancer Therapeutics, highlighting the potential of their lead drug, paxalisib, to overcome immunotherapy resistance in triple-negative breast cancer (TNBC). The research, conducted by Professor Sudha Rao at QIMR Berghofer Medical Research Institute, demonstrated that paxalisib can reprogram the tumor microenvironment and enhance immune response, showing synergy with immune checkpoint inhibitors. This breakthrough supports the ongoing clinical development of paxalisib in combination with other therapies, marking a pivotal step in its application beyond brain cancers and positioning it as a key player in innovative cancer treatments.
The most recent analyst rating on (KZIA) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.
Spark’s Take on KZIA Stock
According to Spark, TipRanks’ AI Analyst, KZIA is a Underperform.
Kazia Therapeutics has a low overall stock score due to significant financial instability marked by declining revenues, negative equity, and cash flow issues. Technical indicators suggest bearish momentum, and poor valuation metrics reflect the company’s unprofitability. The absence of dividends and positive earnings call or corporate events data further emphasize the company’s challenges.
To see Spark’s full report on KZIA stock, click here.
More about Kazia Therapeutics
Kazia Therapeutics Limited is a clinical-stage biotechnology company based in Sydney, Australia, focusing on the development of oncology therapeutics. Their lead program is paxalisib, an investigational inhibitor targeting the PI3K/Akt/mTOR pathway, primarily developed for brain cancer treatment. The company is also working on EVT801, a small molecule inhibitor of VEGFR3, with potential applications in various tumor types.
Average Trading Volume: 28,749
Technical Sentiment Signal: Sell
Current Market Cap: $5.87M
See more data about KZIA stock on TipRanks’ Stock Analysis page.